The Toll–Like Receptor 2/6 Agonist, FSL–1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
research suggests that the toll-like receptor 2/6 agonist, fsl-1 lipopeptide, may have a therapeutic effect on acute radiation syndrome. this finding indicates a potential treatment for the condition. the fsl-1 lipopeptide is reported to mitigate acute radiation syndrome.